BIOLIFE SOLUTIONS INC

BioLife Solutions’ merger with Repligen could boost growth, keep its products like cryostor and bloodstor, and shift the company into a wholly owned subsidiary by Q4 2026.

BioLife Solutions Inc’s financial journey is marked by volatility, but its focus on the cell and gene therapy market positions it for future success despite short-term challenges.

BioLife Solutions Inc. is set to release its Q1 2025 financial results on May 8, 2025, a critical moment for the company as it navigates the challenges of the cell and gene therapy market.